Incyte‘s patent involves compounds that modulate adenosine receptors, potentially treating cancer, inflammatory, cardiovascular, and neurodegenerative diseases. Claim 1 details a method to inhibit adenosine receptor activity using specific compounds. GlobalData’s report on Incyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Incyte, Peptide pharmacophores was a key innovation area identified from patents. Incyte's grant share as of May 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11999740B2) discloses a method for inhibiting the activity of an adenosine receptor by contacting the receptor with a compound of Formula (IIIa). The patent also covers a method for treating various cancers, including bladder cancer, lung cancer, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, prostate cancer, and head and neck cancer, by administering a therapeutically effective amount of the compound of Formula (IIIa). Specific diseases such as non-small cell lung cancer (NSCLC), metastatic castrate-resistant prostate carcinoma (mCRPC), or colorectal carcinoma (CRC) are also included in the treatment method.
The patent further details the specific chemical structures and substitutions within the compound of Formula (IIIa) that are effective in treating the mentioned diseases. Various configurations of the compound, including different aryl and cycloalkyl groups, are described, along with the option for deuterium substitution. Additionally, the patent specifies the use of specific compounds or their pharmaceutically acceptable salts for treating different types of cancers, such as head and neck squamous cell carcinoma, NSCLC, ovarian cancer, metastatic
To know more about GlobalData’s detailed insights on Incyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
